Results 1 to 10 of about 123,913 (326)
Dopamine agonist withdrawal syndrome associated factors: A retrospective chart review [PDF]
Clinical Parkinsonism & Related Disorders, 2022 Dopamine agonist withdrawal syndrome (DAWS) has been introduced to describe the constellation of symptoms resulting from reduction or suspension of dopamine agonist medications.
Xiomara Garcia +4 more
doaj +2 more sources
Could dopamine agonists aid in drug development for anorexia nervosa? [PDF]
, 2014 Anorexia nervosa is a severe psychiatric disorder most commonly starting during the teenage-years and associated with food refusal and low body weight. Typically there is a loss of menses, intense fear of gaining weight, and an often delusional quality ...
Frank, Guido KW
core +4 more sources
Predictors of dopamine agonist resistance in prolactinoma patients [PDF]
BMC Endocrine Disorders, 2020 Background Surgical resection of prolactinomas resistant to dopamine agonists is frequently incomplete due to fibrotic changes of the tumour under pharmacological therapy. In order to identify a subgroup of patients who may benefit from early surgery, we
Elle Vermeulen +6 more
doaj +2 more sources
Dopamine agonist monotherapy utilization in patients with Parkinson’s disease [PDF]
Clinical Parkinsonism & Related Disorders, 2023 Objectives: To characterize patients with Parkinson’s disease (PD) who initiated dopamine agonist (DA) monotherapy, describe medication utilization and provider types, and estimate medication adherence and discontinuation rates.
Monica Frazer +3 more
doaj +2 more sources
Irreversible extreme freezing of gait after dopamine agonist withdrawal [PDF]
Clinical Case Reports, 2021 Dopamine agonist withdrawal can cause freezing of gait in PD patients.
Mehri Salari +4 more
doaj +2 more sources
Dopamine agonist-responsive Cushing's disease. [PDF]
BMJ Case Rep, 2019 A 47-year-old Caucasian man was referred to our clinic with a severe clinical and biochemical phenotype of endogenous hypercortisolism for further evaluation and treatment. In addition to confirming adrenocorticotropic hormone (ACTH)-dependent Cushing’s syndrome, we found left temporal hemianopsia, massively increased prolactin, increased growth ...
Anand G, Bink A, Beuschlein F, Schmid C.
europepmc +5 more sources
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors
Parkinson's Disease, 2021 Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde +2 more
doaj +1 more source
Clinical Parkinsonism & Related Disorders, 2021 Dopamine agonists are one of the main stay of treatment option for Parkinson disease (PD). Side effects that develop from their use are generally categorized into behavioral and non-behavioral.
Mohammad Edrees Mohammad +6 more
doaj +1 more source
An approach for identifying brainstem dopaminergic pathways using resting state functional MRI. [PDF]
, 2014 Here, we present an approach for identifying brainstem dopaminergic pathways using resting state functional MRI. In a group of healthy individuals, we searched for significant functional connectivity between dopamine-rich midbrain areas (substantia nigra;
D'Esposito, Mark +3 more
core +8 more sources
Dopamine inhibits mitochondrial motility in hippocampal neurons. [PDF]
PLoS ONE, 2008 The trafficking of mitochondria within neurons is a highly regulated process. In an earlier study, we found that serotonin (5-HT), acting through the 5-HT1A receptor subtype, promotes axonal transport of mitochondria in cultured hippocampal neurons by ...
Sigeng Chen +2 more
doaj +1 more source